[1] Re VL,Kallan MJ,Tate JP,et al.Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients:a cohort study. Ann Intern Med,2014,160(6):369-379. [2] Manns M,Pol S,Jacobson IM,et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational,phase 3,multicohort study. Lancet,2018,384(9954):1597-1605. [3] Fujimoto K,Kato M,Kudo M,et al.Novel image analysis method using ultrasound elastography for noninvasive evaluation of hepatic fibrosis in patients with chronic hepatitis C. Oncology,2013,84(Suppl 1):3-12. [4] Lim JK, Tate JP,Fultz SL,et al.Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected,chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis,2014,58(10):1449-1458. [5] Kim WR,Berg T,Asselah T,et al.Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol,2016,64(4):773-780. [6] Noureddin M,Wright EC,Aster HJ,et al.Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C:a longitudinal analysis. Hepatology,2013,58(5):1548-1557. [7] Arena U,Lupsor Platon M,Stasi C,et al.Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology,2013,58(1):65-72. [8] 姚轶男,黄鹏,陈红波,等. 江苏省句容市既往有偿献血人群慢性丙型肝炎重度肝纤维化影响因素研究.中华流行病杂志,2017,38(1):49-52. [9] 谢琴秀,徐楠,江晓平,等. FibroScan对慢性乙型肝炎病毒感染者肝纤维化评估的影响因素分析.中华肝脏病杂志,2016,24(9):659-664. [10] 张婷,张航,郝峥,等. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析. 实用肝脏病杂志,2017,20(5):602-603. [11] 朱传龙,朱甜甜,王坤,等.慢性丙型肝炎患者血清Pygo2水平对肝纤维化程度的评估价值探讨.实用肝脏病杂志,2017,20(2):161-164. [12] Konerman MA,Mehta SH,Sutcliffe CG,et al.Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults:prospective analysis of 435 liver biopsy pairs. Hepatology,2014,59(3):767-775. [13] 李俊峰,郑素军,段钟平,等. 慢性丙型肝炎自然史影响因素的研究进展. 中华肝脏病杂志,2015,23(6):475-477. [14] Holmberg SD,Lu M,Rupp LB,et al.Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis,2013,57(2):240-246. [15] Vergniol J,Boursier J,Coutzac C,et al.Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology,2014,60(1):65-76. [16] Negash AA,Ramos HJ,Crochet N,et al.IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog,2013,9(4):1-13. [17] Poordad F,Schiff ER,Vierling JM,et al.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology,2016,63(5):1493-1505. [18] Leung VY,Shen J,Wong VW,et al.Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers:comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology,2013,269(3):910-918. [19] Lee Y,Lee JM,Lee JE,et al.MR elastography for noninvasive assessment of hepatic fibrosis:reproducibility of the examination and reproducibility and repeatability of the liver stiffness value measurement. J Magn Reson Imaging,2014,39(2):326-331. [20] Younossi ZM,Stepanova M,Afdhal N,et al.Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol,2015,63(2):337-345. |